Advances in Therapy Martinez-Calle, N, Kirkwood, A A, Lamb, M, Smith, A, Khwaja, J, Manos, K, Shrubsole, C, Gray, N, Lewis, K, Tivey, A, Bishton, M J, Hawkes, E, Ahearne, M J, Osborne, W, Collins, G P, Illidge, T, Linton, K M, Cwynarski, K, Burton, C & Fox, C P 2021, ' Systemic ALCL Treated in Routine Clinical Practice : Outcomes Following First-Line Chemotherapy from a Multicentre Cohort ', Advances in Therapy, vol. 38, no. 7, pp. 3789-3802 . https://doi.org/10.1007/s12325-021-01764-0
Fox, C P, Ahearne, M J, Pettengell, R, Dearden, C E, El-Sharkawi, D, Kassam, S, Cook, L, Cwynarski, K, Illidge, T & Collins, G 2022, ' Guidelines for the management of mature T-and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline ', British Journal of Haematology|B J H, vol. 196, no. 3, pp. 507-522 . https://doi.org/10.1111/bjh.17951
Smith, V, Mukherjee, D, Lunj, S, Choudhury, A, Hoskin, P, West, C & Illidge, T 2021, ' The effect of hypoxia on PD-L1 expression in bladder cancer ', BMC Cancer, vol. 21, no. 1, 1271, pp. 1271 . https://doi.org/10.1186/s12885-021-09009-7 BMC Cancer BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Br J Radiol Illidge, T & Phillips, B 2021, ' Progress and pitfalls with the use of image-guided personalised approaches in lymphoma ', British Journal of Radiology, vol. 94, pp. 20210609 . https://doi.org/doi.org/10.1259/bjr.20210609
Iyer, S, Trümper, L, O’Connor, O A, Pro, B, Illidge, T, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Menne, T, Belada, D, Illès, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Zinzani, P L, Miao, H, Bunn, V, Fenton, K, Fanale, M, Puhlmann, M & Horwitz, S 2021, ' Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma ', Clinical Lymphoma Myeloma and Leukemia, vol. 21, no. Suppl. 1, pp. S203 . https://doi.org/10.1016/S2152-2650(21)01276-3
Nakamura, K, Karmokar, A, Farrington, P M, James, N H, Ramos-Montoya, A, Bickerton, S J, Hughes, G D, Illidge, T M, Cadogan, E B, Davies, B R, Dovedi, S J & Valge-Archer, V 2021, ' Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 15, pp. 4353-4366 . https://doi.org/10.1158/1078-0432.CCR-20-3701